Craig-Hallum analyst Chase Knickerbocker lowered the firm’s price target on Bioventus (BVS) to $15 from $17 and keeps a Buy rating on the shares following quarterly results. The company noted that tariff exposure thus far remains minimal at less than $1M and is included in guidance. Though the firm says there may be additional risk from pharma tariffs on HA products, which have thus been excluded from the first round of tariffs.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BVS: